e-Lung: a fully automated, AI-powered solution for assessment of Interstitial Lung Disease (ILD)

Interstitial Lung Diseases (ILDs) are a broad category of over 200 lung diseases that can cause scarring (fibrosis) to the lungs. The damage caused to the lungs from ILDs is often irreversible and can get worse over time. Early and accurate diagnosis is key to getting patients access to the right treatment and improving quality of life.

There is a growing need for more accurate and reproducible assessment and quantification of ILD in order to get patients access to the right treatment at an earlier timepoint and to improve the success of clinical trials.

Brainomix’ e-Lung solution has been trained using thousands of CT scans from leading academic institutions to accurately quantify pulmonary fibrosis and other characteristics using proprietary imaging biomarkers.

e-Lung provides accurate and objective quantification of disease progress over time and can also identify patients that are at risk of progression.

Recent data presented at ATS and ERS from Brainomix demonstrated e-Lung's capability to predict both short- and long-term outcomes in Idiopathic Pulmonary Fibrosis (IPF) and non-IPF cohorts, including relative Forced Vital Capacity (FVC) decline and survival. When compared to current standard measures, including FVC and radiological assessment, e-Lung was a better predictor of survival when assessing change between two timepoints.

Bmx E Lung 600X600px

AI-powered biomarkers from e-Lung are available now for use in clinical trials to:

Objectively assess treatment response

Predict disease behavior and outcomes from baseline imaging

Explore and characterize responsive phenotypes

Hear from our valued partners and collaborators

Contact us today

Speak with us to learn how to integrate our ILD biomarkers into your clinical trials and clinical research.

Our Partners

Leave Your Legacy Portuguese Logo
Boehringer Ingelheim Logo
Nvidia Logo
GE Healthcare
Wallaby Logo
Fora Logo